Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Prostate Cancer | Research

Predictors of participants’ retention—socioeconomic factors or nonadherence: insights from a urological clinical prospective study

Authors: Allison J. Wheeler, Harshit Garg, Dharam Kaushik, Ahmed Mansour, Deepak Pruthi, Michael A. Liss

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

To investigate various patient-level variables, specifically socioeconomic status, as risk factors for withdrawal in a recently completed clinical study. We specifically investigated a non-interventional prospective study assessing the role of novel imaging as a biomarker for cancer upgradation in prostate cancer for this objective.

Methods

In this retrospective analysis, we assessed the association between various patient-level factors including clinic-demographic factors, socioeconomic status, and the number of non-adherences with the participants’ retention or withdrawal from the study. For socioeconomic status (SES), we used the zip code–based Economic Innovation Group Distressed Community Index (DCI) which classifies into five even distress tiers: prosperous, comfortable, mid-tier, at-risk, or distressed. Low SES was defined as those with a DCI Distress tier of at-risk or distressed. We compared values between the two retention and withdrawal groups using t-test, chi-square test, and logistic regression analysis.

Results

Of 273 men screened, 123 men were enrolled. Among them, 86.2% (106/123) retained through the study whereas 13.8% (17/123) withdrew from the study. The mean (SD) age was 64 (6.4) years. Overall, 31.7% (39/123) were Hispanics and 24.3% (30/123) were African Americans. The median (IQR) DCI score was 34 (10.3, 68.1) and 30.8% (38/123) of patients belonged to low SES. The median DCI score in participants who retained in the study was statistically similar to those who withdrew from the study (p=0.4). Neither the DCI tiers (p=0.7) nor the low SES (p=0.9) were associated with participants’ retention or withdrawal of the study. In terms of non-adherence, all participants in the withdrawn group had at least one non-adherent event compared to 48.1% in the retained group (p<0.001). Repetitive non-adherence was significantly higher in participants who withdrew from the study vs those who retained in the study [88.2% vs 16.9%, p <0.001]. On multivariate logistic regression analysis, the number of non-adherences (OR=12.5, p<0.001) and not DCI (OR=0.99, p=0.7) appeared to be an independent predictor for participants’ retention or withdrawal from the study.

Conclusions

Expanding diverse inclusion and limiting withdrawal with real-time non-adherence monitoring will lead to more efficient clinical research and greater generalizability of results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7:e015276.CrossRefPubMedPubMedCentral Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7:e015276.CrossRefPubMedPubMedCentral
3.
go back to reference Baah FO, Teitelman AM, Riegel B. Marginalization: Conceptualizing patient vulnerabilities in the framework of social determinants of health – An integrative review. Nurs Inq. 2020;26:e12268.CrossRef Baah FO, Teitelman AM, Riegel B. Marginalization: Conceptualizing patient vulnerabilities in the framework of social determinants of health – An integrative review. Nurs Inq. 2020;26:e12268.CrossRef
5.
go back to reference Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228.CrossRefPubMed Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228.CrossRefPubMed
6.
go back to reference Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials. 2014;39:169.CrossRefPubMedPubMedCentral Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials. 2014;39:169.CrossRefPubMedPubMedCentral
7.
go back to reference Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105.CrossRefPubMed Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105.CrossRefPubMed
8.
go back to reference Bower P, Brueton V, Gamble C, et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials. 2014;15:399.CrossRefPubMedPubMedCentral Bower P, Brueton V, Gamble C, et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials. 2014;15:399.CrossRefPubMedPubMedCentral
9.
go back to reference Daykin A, Clement C, Gamble C, et al. ‘Recruitment, recruitment, recruitment’ – the need for more focus on retention: a qualitative study of five trials. Trials. 2018;19:76.CrossRefPubMedPubMedCentral Daykin A, Clement C, Gamble C, et al. ‘Recruitment, recruitment, recruitment’ – the need for more focus on retention: a qualitative study of five trials. Trials. 2018;19:76.CrossRefPubMedPubMedCentral
13.
go back to reference Economic Innovation Group Methodology. Distressed Communities Index, (n.d.). Web. These data were retrieved from the following resource available in the public domain: https://eig.org/dci. Retrieved November 23, 2020. Economic Innovation Group Methodology. Distressed Communities Index, (n.d.). Web. These data were retrieved from the following resource available in the public domain: https://​eig.​org/​dci. Retrieved November 23, 2020.
14.
go back to reference Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals From 2008 to 2018. JAMA Oncol. 2019;5:e191870.CrossRefPubMedPubMedCentral Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals From 2008 to 2018. JAMA Oncol. 2019;5:e191870.CrossRefPubMedPubMedCentral
15.
go back to reference Unger JM, Gralow JR, Albain KS, et al. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol. 2016;2:137.CrossRefPubMedPubMedCentral Unger JM, Gralow JR, Albain KS, et al. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol. 2016;2:137.CrossRefPubMedPubMedCentral
17.
go back to reference Mehaffey JH, Hawkins RB, Charles EJ, Turrentine FE, Hallowell PT, Friel C, et al. Socioeconomic "Distressed Communities Index" improves surgical risk-adjustment. Ann Surg. 2020 Mar;271(3):470–4.CrossRefPubMed Mehaffey JH, Hawkins RB, Charles EJ, Turrentine FE, Hallowell PT, Friel C, et al. Socioeconomic "Distressed Communities Index" improves surgical risk-adjustment. Ann Surg. 2020 Mar;271(3):470–4.CrossRefPubMed
19.
go back to reference DeLozier S, Speltz P, Brito J, Tang LA, Wang J, Smith JC, et al. Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. J Am Med Inform Assoc. 2021;28(1):126–31. https://doi.org/10.1093/jamia/ocaa213. PMID: 33120413; PMCID: PMC7810433. DeLozier S, Speltz P, Brito J, Tang LA, Wang J, Smith JC, et al. Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. J Am Med Inform Assoc. 2021;28(1):126–31. https://​doi.​org/​10.​1093/​jamia/​ocaa213. PMID: 33120413; PMCID: PMC7810433.
20.
go back to reference Goldberg RM, Sargent DJ, Morton RF, et al. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group’s real-time toxicity monitoring program. J Clin Oncol. 2002;20:4591.CrossRefPubMed Goldberg RM, Sargent DJ, Morton RF, et al. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group’s real-time toxicity monitoring program. J Clin Oncol. 2002;20:4591.CrossRefPubMed
21.
go back to reference Munnoch SA, Cashman P, Peel R, et al. Participant-Centered Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study. J Med Internet Res. 2019;21:e14791.CrossRefPubMedPubMedCentral Munnoch SA, Cashman P, Peel R, et al. Participant-Centered Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study. J Med Internet Res. 2019;21:e14791.CrossRefPubMedPubMedCentral
22.
go back to reference Pietanza MC, Basch EM, Lash A, et al. Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol. 2013;31:2004.CrossRefPubMedPubMedCentral Pietanza MC, Basch EM, Lash A, et al. Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol. 2013;31:2004.CrossRefPubMedPubMedCentral
23.
go back to reference Dockendorf MF, Hansen BJ, Bateman KP, Moyer M, Shah JK, Shipley LA. Digitally enabled, patient-centric clinical trials: shifting the drug development paradigm. Clin Transl Sci. 2021;14(2):445–59. https://doi.org/10.1111/cts.12910. Epub 2020 Nov 30. PMID: 33048475; PMCID: PMC7993267. Dockendorf MF, Hansen BJ, Bateman KP, Moyer M, Shah JK, Shipley LA. Digitally enabled, patient-centric clinical trials: shifting the drug development paradigm. Clin Transl Sci. 2021;14(2):445–59. https://​doi.​org/​10.​1111/​cts.​12910. Epub 2020 Nov 30. PMID: 33048475; PMCID: PMC7993267.
Metadata
Title
Predictors of participants’ retention—socioeconomic factors or nonadherence: insights from a urological clinical prospective study
Authors
Allison J. Wheeler
Harshit Garg
Dharam Kaushik
Ahmed Mansour
Deepak Pruthi
Michael A. Liss
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06901-w

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue